Novo Nordisk A/S (NYSE:NVO) Holdings Increased by New Republic Capital LLC

New Republic Capital LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 52.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,677 shares of the company’s stock after purchasing an additional 1,261 shares during the period. New Republic Capital LLC’s holdings in Novo Nordisk A/S were worth $316,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC grew its holdings in Novo Nordisk A/S by 40.3% during the third quarter. Exchange Traded Concepts LLC now owns 63,962 shares of the company’s stock worth $7,616,000 after acquiring an additional 18,370 shares during the period. Procyon Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 6.7% in the third quarter. Procyon Advisors LLC now owns 63,649 shares of the company’s stock valued at $7,579,000 after buying an additional 4,010 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $313,000. Sapient Capital LLC boosted its stake in shares of Novo Nordisk A/S by 0.7% during the 3rd quarter. Sapient Capital LLC now owns 640,279 shares of the company’s stock worth $76,238,000 after acquiring an additional 4,429 shares in the last quarter. Finally, Adamsbrown Wealth Consultants LLC increased its stake in Novo Nordisk A/S by 13.8% in the 3rd quarter. Adamsbrown Wealth Consultants LLC now owns 1,916 shares of the company’s stock worth $228,000 after purchasing an additional 233 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.9 %

Shares of Novo Nordisk A/S stock opened at $83.90 on Tuesday. The company has a market cap of $376.48 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company’s fifty day simple moving average is $91.46 and its 200-day simple moving average is $111.21. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

Analysts Set New Price Targets

Several research analysts have commented on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.